We are interested in establishing alliances to develop and access novel:
Medicinal Chemistry Synthesis Technology
Synthetic technologies that can accelerate the drug discovery process, including high-throughput chemistry, parallel medicinal chemistry, synthetic lab automation, biocatalysis, flow chemistry, photo- and electrochemistry
Broadly applicable computational platforms to predict chemical reaction outcomes
Synthetic methodologies for late-stage diversification
Synthetic methodologies to access small, conformationally constrained multifunctional templates
Novel monomers and building blocks in drug-like property space
Medicinal Chemistry
Small molecule approaches to expand NCE target space – RNA splicing or translational modulation, non-CRBN and non-VHL mediated strategies for targeted protein degradation, heterobifunctional and/or molecular glue strategies to co-opt post-translational protein modification (i.e., ubiquitylation, deubiquitylation, phosphorylation) and/or induce protein mislocalization, modulation of protein-protein interactions and non-Ro5 compounds
Solute ligand carrier, transcription factor, deubiquitylating (DUB) enzyme, phosphatase, RNA binding protein, and biomolecular condensate modulator design and screening technologies
Strategies to facilitate the conversion of Ab therapeutics to orally administered therapies
New technologies to generate orally available peptides and peptidomimetics
AI/ML methodologies to predict novel protein or RNA structures and their complexes with small molecules or other biomolecules
Membrane protein structural biology technologies and capabilities, including ion channels, GPCRs and solute carrier proteins
DNA-compatible synthetic protocols and DNA backbone modifications that expand currently available methodology for DNA-encoded libraries (DEL). Strategies to screen DEL libraries in cells and/or for membrane proteins.
Computational methods for quantitative affinity prediction and molecular dynamics simulation
Technologies to identify hits through virtual screening of very large compound collections
Systems/chemical biology technologies enabling mechanism determination for phenotypic screening hits
Morphological or transcriptional profiling technologies to enable hit expansion and pathway inferences for phenotypic screening
Pharmacokinetics Dynamics and Metabolism (PDM)
Translation
Translational modeling and simulation approaches, systems pharmacology/PK-PD; deep knowledge of targets/pathways; increased confidence in target drug selection
Bioanalysis and biomarkers
Novel bioanalytical and cellular imaging techniques
Specific biomarkers of ADME DDI liability (both transporter and enzyme biomarkers)
Novel methodology for pull-down of tissue specific exosomes
Disposition and delivery of therapies
Novel commercially viable delivery technologies (oral and non-oral)
Biodistribution of nanoparticles at whole organ and cellular level
Targeting, prediction and modeling of transporter-mediated disposition and DDIs – small molecules
Quantitation and scaling of transporters for input into physiological PK models of tissue penetration and clearance including biliary clearance
Novel approaches and technology to achieving selective tissue distribution (including receptor mediated and transporter mediated strategies for therapeutic window enablement
Determination of intracellular/sub-cellular unbound concentrations of transported drugs
Transformative in vitro assays such as PK and PKPD on a chip
Predictive in vitro or in silico absorption (fafg) models